SUMMARY Resistance and side effects to antibiotics or other chemotherapeutic agents are the main limiting factors in the treatment ofgonorrhoea. As no such side effects have been reported with a new aminoglycoside, netilmicin, the therapeutic efficiency of this substance was evaluated in 1200 patients (690 women, 510 men) with uncomplicated gonorrhoea, who each received a single dose of 300 mg netilmicin by intramuscular injection. Efficacy of treatment was assessed by smear microscopy and culture, which gave negative results in all 1200 patients. No serious side effects were reported.
Introduction
The development ofresistance, treatment failures, and side effects, particularly allergic and toxic reactions to antibiotics and chemotherapeutic agents, account for the major problems in treating gonorrhoea.
It has been estimated that resistance ofgonococci to penicillin can be expected in more than 40 countries in the world.' In Europe increasing numbers of penicillinase producing Neisseria gonorrhoeae (PPNG) strains have been observed. In addition, some PPNG strains have shown resistance to spectinomycin, which possibly indicates a new trend in the pattern of resistance of gonoccoci.26 Another disadvantage of penicillins is a relatively high rate of allergic reactions, which might be life threatening or even fatal in some cases. Injections of 300 mg netilmicin in patients with a median weight of 80 kg resulted in maximum peak serum concentrations of 14 mg/i after 45 minutes. The mean serum half life of Netilmicin was two hours, 70-80% ofthe active drug being excreted in the urine after 24 hours.
All patients were cured, no serious side effects were reported, no allergic reactions occurred, and no signs of nephrotoxicity or ototoxicity developed.
Discussion
According to our test results, with a median MIC of 3.57 mg/l, and a published report of values below 2 mg/1,'7 serum concentrations after intramuscular injection of 300 mg netilmicin far exceed the MIC for gonococci. The pattern of susceptibility of the nine PPNG strains to netilmicin was comparable with that of other strains. Though serum concentrations for patients weighing less than 60 kg may reach the upper limits of safety, toxic effects are unlikely for the following reasons: the serum half life of netilmicin is 1.65 to 2.7 hours for patients with normal renal function;'8 after single dose treatment 70-90% of the drug is excreted within 24 hours, and exposure to the substance is therefore minimal.
There are no data about the activity of netilmicin against Treponemapallidum, but it can be concluded that netilmicin is inactive, as gentamicin and sisomicin show no activity.'9 Netilmicin therefore probably does not influence incubating syphilis. There is also no activity against Chlamydia trachomatis.20 One step mutation to resistance to modern aminoglycosides rarely occurs 3' 22 The fear of development of resistant strains, treatment failures, and side effects are the reasons that new compounds are regularly tested for the treatment of gonorrhoea. Apart from spectinomycin, an aminocyclitol antibiotic whose chemical structure is closely related to that of aminoglycosides, aminoglycosides have not been used in central Europe to treat gonorrhoea. The reason for the restricted use of aminoglycosides is concern that resistance may develop by one step mutation, which would have a negative effect on their use in treating systemic infections. Recent evaluations, however, have shown that newly developed aminoglycosides do not have a tendency to cause rapid development of resistance32' Studies using single dose treatment with an aminoglycoside have not resulted in such a development?33
The most common mechanism of bacterial resistance to aminoglycosides is a modification of the drug by enzymes . This results in a blockade ofthe transport of the antibiotic into the cell. Resistance to aminoglycosides is mainly transferred by plasmids.
Netilmicin: new approach to treating gonorrhoea Three major enzymes are known that can inactivate aminoglycosides, but only one, acetyl transferase, can affect netilmicin.24 This important difference from other aminoclycosides is one ofthe reasons for the low risk of rapid development of resistant strains. 25 Aminoglycosides have been used for single dose treatment of uncomplicated urinary tract infections without inducing a rapid change in resistance patterns. 23 Our results show that 300 mg netilmicin given as a single injection is an effective treatment for gonorrhoea .Exposure to the drug is low, and the risk of side effects is reduced to a minimum. Resistant strains have not been observed. There is no relevant tendency for the susceptibility pattern to change . It can therefore be concluded that netilmicin is a safe and effective drug for the treatment of uncomplicated gonorrhoea.
